I concur. Have NTRP investors looked at the track record of drugs seeking to boost growth factors? Case in point, M3 Biosciences out of Washington state. Back in 2014 there was a lot of hype surrounding this privately held company, much like there is now surrounding NTRP. Its Alzheimers drug had/has same MOA as brysotatin, boost growth factor levels. NIH and a foundation were funding its early trials. A trial enrolling, I believe, 450 patients flamed out. The company hasn't given up on the drug, although its been stalled. Their website is a joke, no listing their pipeline or trial progress.
Bryostatin fails to correct the cause of the Alzheimers, mitochondrial dysfunction. The first thing to show up in pre Alzheimers patients is mitochondrial dysfunction, not low levels of PKE epsilon. Anavex's sigma 1 drugs correct mitochondrial dysfunction, as well as stimulating regulated synaptogenesis
It dumbfounds me that the goal of Neurotrope is to stimulate synaptogenesis yet they don't bother to include P300 testing in their trials.
I think there is a 50/50 chance NTRP will crash post Ph 2b results no matter the results.
Market Data 
Markets 
AI
